Abstract The development of biomaterials for efficient intracellular delivery of the nucleic acid-based immunestimulating molecule, CpG oligodeoxynucleotides (CpG), is crucial for their biological activity. In this study, we successfully fabricated polydopamine-coated porous poly(lactic-co-glycolic acid) microparticles (PPM) for the delivery of CpGs. After conjugation of CpGs to PPMs via cleavable disulfide linkages, CpGs were readily released from CpGconjugated PPM (PPM-s-s-CpGs) in reductive conditions. Released CpGs exhibited significantly enhanced induction of two cytokines, TNF-a and IL-6, in RAW264.7 cells. GpCconjugated PPMs showed negligible cytokine induction, whereas CpG-conjugated PPMs exhibited strong induction of the two cytokines in RAW264.7 cells. The PPM-s-s-CpGs can serve as immune-stimulating adjuvants to enhance the immune responses of vaccines.
Introduction
Pathogens are detected by host cells via the interactions between biomolecules on the pathogen and pathogen recognition receptors (PRRs), e.g., toll-like receptors (TLRs), on cellular surfaces or intracellular regions of the host cell, which trigger signal transduction pathways and induce local and systemic immune response. Biomolecules of pathogens that are recognized by PRRs are known as pathogen-associated molecular patterns (PAMPs), e.g., host gene product, host-specific protein, and lipopolysaccharides (LPS) [1] . Recently, PAMPs have been popularly investigated as adjuvant materials [2, 3] . The administration of adjuvants with antigens has several advantages, including the induction of immune responses with low doses of antigens, rapid immune response, and enhanced cytotoxic T cell response [4] . Currently, several types of adjuvants, including monophosphoryl lipid A (MPLA), double-stranded RNA, and CpG oligodeoxynucleotides (CpG), have already been under clinical trial [5] . For example, polyriboinosinic:polyribocytidylic acid (poly I:C), a double-stranded RNA, induced increased interleukin-12 production, elevated maturation of dendritic cells, and enhanced memory T cell response by T helper cell 1 and cytotoxic T lymphocytes in an antigen-specific manner [6, 7] . CpG has also been considered as biocompatible adjuvants [8] . While mammalian CpG sequences with methylation have poor binding capacity with TLR-9, bacterial CpG sequences without methylation bind TLR-9 and induce strong immune responses [9] [10] [11] . Singlestranded DNA with CpG sequences binds to TLR-9 in endosomes after cellular uptake, which triggers the NF-jB pathway, cytokine induction, and activation of antigenpresenting cells [12] . Currently, several CpGs are under clinical trial [5, 13] . However, CpGs have high molecular weight and negative charge, which hinder endosomal localization for binding to TLR-9. In addition, enzymatic degradation can be an obstacle for the successful in vivo treatment with CpGs. To overcome these challenges, different types of biomaterials based on lipids/polymers have been designed to protect CpGs from DNase, improve circulation time, and elevate uptake in target cells [8, [14] [15] [16] .
Poly(lactic-co-glycolic acid) (PLGA), a biodegradable polymer approved by the Food and Drug Administration, has been conventionally used for particle formulation [17, 18] . In our previous study, porous and microsized particles formulated using PLGA via water-in-oil-in-water (W 1 /O/W 2 ) double emulsion and solvent evaporation processes were coated with polydopamine to conjugate and deliver CpGs via non-cleavable linkages [19] . However, stimuli-responsive behavior and cleavable linkage have not been investigated for the delivery of CpGs using polydopamine-coated porous microparticles (PPMs).
In this study, CpGs were conjugated via cleavable disulfide linkages onto PPMs (PPM-s-s-CpG) for facile interactions with TLR-9. The particle size and morphology of the prepared PPM-s-s-CpG were examined by scanning electron microscopy (SEM). The release profiles of CpGs from PPM-s-s-CpGs were investigated in the presence of a reducing agent, dithiothreitol (DTT). The release of two cytokines, interleukin-6 (IL-6) and tumor necrosis factoralpha (TNF-a), by PPM-s-s-CpGs was quantitatively evaluated by enzyme-linked immunosorbent assay (ELISA) after transfection of RAW264.7 cells.
Materials and methods

Materials
Poly(lactic-co-glycolic acid) (PLGA, RG503H) was purchased from Boehringer Ingelheim (Ingelheim am Rhein, Germany 0 -TCCATGAGCTTCCTGAGCTT-3 0 ) at the 3 0 -end were obtained from Bioneer (Daejeon, South Korea). Succinimidyl 3-(2-pyridyldithio) propionate (SPDP) was purchased from Thermo Scientific (Rockford, IL, USA). Dithiothreitol (DTT) was obtained from Duchefa Biochemie (Haarlem, BH, Netherlands). OliGreen Ò ssDNA Quantitation Assay Kit was purchased from Molecular Probes (Eugene, OR, USA). Mouse IL-6 and TNF-a enzyme-linked immunosorbent assay (ELISA) kits were purchased from BD Biosciences (Franklin Lake, NJ, USA). Dulbecco's modified Eagle's medium (DMEM), penicillin/ streptomycin (P/S), and fetal bovine serum (FBS) were purchased from Gibco BRL (Grand Island, NY, USA). All other chemicals were of analytical grade.
Preparation of PPM-s-s-CpG
Porous spherical PLGA microspheres were formulated according to our previous study [14] . BPEI (2 mg) in 50 lL of deionized water (W 1 ) was first dispersed in 400 lL of methylene chloride containing PLGA (20 mg) via brief sonication for 1 min, using a tip sonicator (Branson Digital Sonifier Ò 450, Danbury, CT, USA). The primary W 1 /O emulsion solution was then added drop-wise to 8 mL of aqueous solution (W 2 ) containing 1% PVA before sonication for 150 s. Hardened microspheres via overnight stirring were centrifuged at 10,000 rpm for 10 min, resuspended in deionized water (DW) at a polymer concentration of 1 mg/mL, centrifuged for washing three times with DW, and freeze-dried. For polydopamine coating, dopamineÁHCl (300 lg) in DW was added to Tris buffer solution (10 mM Tris-HCl, pH 8.5) containing dried porous PLGA microspheres (300 lg) and mixed by vigorous stirring for 3 h as previously described [20] . The resulting polydopamine-coated and PPMs were purified via centrifugation at 10,000 rpm for 10 min to remove free dopamine.
For the preparation of cleavable CpG oligodeoxynucleotides, 3
0 -amine-modified CpG (CpG-NH 2 , 31.2 lg) or 3 0 -amine-modified GpC (GpC-NH 2 , 31.2 lg) in phosphate buffered solution (PBS pH 8.0) was mixed with SPDP (156 lg) in dimethyl sulfoxide and stirred overnight at 200 rpm at a molar ratio of oligodeoxynucleotides:SPDP = 1:100. Excessive SPDP was eliminated via dialysis (molecular weight cutoff, MWCO = 3.5 kDa) with DW at room temperature for 1 day. The purified reactant in PBS (pH 8.0) was mixed with cysteamine (38.6 lg) in dimethylformamide and stirred overnight at 200 rpm at a molar ratio of feed oligodeoxynucleotides:-cysteamine = 1:100. The resulting CpG and GpC with disulfide linker (CpG-s-s-NH 2 and GpC-s-s-NH 2 ) were purified via dialysis (MWCO = 3.5 kDa) with DW at room temperature for 1 day and freeze-dried.
For the preparation of CpG-conjugated PPMs via cleavable disulfide linkage (PPM-s-s-CpG), PPM (100 lg) in Tris buffer (10 mM, pH 8.5) was mixed with CpG-s-s-NH 2 (200 lg) in Tris buffer (10 mM, pH 8.5) and stirred overnight. After incubation, the solution was centrifuged (10,000 rpm, 5 min, 4°C) to remove unbound CpG-s-s-NH 2 and washed with DW and 1 lg/lL heparin solution (100 lL). PPM-s-s-GpCs and non-cleavable PPM-CpG were also prepared using GpC-s-s-NH 2 and CpG-NH 2 by the same protocol, respectively. PPMs and PPM-s-s-CpG were observed by SEM (Hitachi S-4800, Tokyo, Japan). Dried microparticles on silicon were vacuum-coated with a thin layer of gold particles. The average size of different microspheres was determined by measuring the diameter of the microspheres.
Time-dependent release profile of PPM-s-s-CpG
PPM-CpG and PPM-s-s-CpG were incubated in the presence of DTT for 10 min. Released CpGs were loaded onto a 15% polyacrylamide gel for polyacrylamide gel electrophoresis (PAGE). To inhibit ionic interactions between the released CpGs and PPMs, heparin (32 lg) in PBS solution was added before gel electrophoresis. To visualize DNA in gels, ethidium bromide was used for staining. The released CpGs were quantitatively measured after the two types of particles, PPM-CpG and PPM-s-s-CpG, and were incubated for predetermined time intervals (0, 0.5, 1, 3, and 5 h) in the presence of DTT (200 mM) in PBS (pH 8.0). After purification with a desalting column (7 kDa), the amount of released CpGs was measured by OliGreen assay according to the manufacturer's protocol.
Cytokine release
RAW264.7 cells (murine macrophage cell line) were maintained in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 lg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO 2 . RAW264.7 cells were plated in 24-well plates at a density of 8 9 10 4 cells/well 24 h prior to treatment. PPM-s-s-CpGs and PPM-s-s-GpCs were incubated with cells for 8 h at a final CpG concentration of 3 lg/mL. Then, the medium was replaced with fresh culture medium containing serum proteins, and cells were further incubated for 16 h. The levels of cytokines (IL-6 and TNF-a) released from the cells were quantified by ELISA. Data in this study represent mean values of independent measurements, and error bars represent standard deviations.
Results and discussion
Preparation of PPM-s-s-CpG
In this study, amine-modified cleavable CpG (CpG-s-s-NH 2 ) was used for covalent conjugation onto PLGA microparticles for the delivery of the immune-stimulating biomolecule, CpG, via phagocytosis into macrophages, as shown in Fig. 1A . In particular, cleavable disulfide bonds were incorporated into CpGs for facile release from microparticles after intracellular uptake. CpG-NH 2 was reacted with SPDP to produce pyridyldithiol-activated CpGs. By treatment with excessive cysteamine, pyridine 2-thione was released and CpG-s-s-NH 2 was obtained. To provide sufficient surface area for the conjugation of CpG, porous structures were fabricated using bPEI as porogens, which allowed high loading capacity in our previous study [19] . For facile chemical conjugation of CpG-s-s-NH 2 onto PLGA microparticles, dopamine polymerization was utilized [21] . The amine groups of CpGs formed covalent bonds with PPMs via Michael-type addition and Schiff base reaction [22] . Figure 1B shows the intracellular processes of PPM-s-s-CpGs. After intracellular uptake of PPM-s-s-CpGs via phagocytic pathways, phagosomal fusion with lysosomes resulted in an enzyme-rich environment, e.g., DNase 2. In addition, the intracellular environment exhibited reductive conditions, which are desirable for the release of CpG from the PPMs via the cleavage of disulfide bonds. Released CpG might freely interact with TLR-9, which triggers intracellular pathways related to immune responses. Figure 2 shows the SEM images of PPM and PPM-s-s-CpGs. As previously reported, porous and spherical microparticles with a diameter of around 2 lm were successfully prepared. After the conjugation of CpGs, the porous structure of PPM-s-s-CpG remained similar to that of PPMs.
Time-dependent release profile of PPM-s-s-CpG
To examine whether CpGs could be released from microparticles in reductive conditions, CpG-conjugated microparticles with non-cleavable and cleavable linkages, PPM-CpG and PPM-s-s-CpG, were incubated in PBS with DTT. After 10 min of incubation, each sample was loaded for PAGE. Figure 3A shows the migration of CpGs released from PPMs. While negligible amounts of CpGs were released from both types of microparticles in the absence of a reducing agent, CpGs were successfully released only from PPM-s-s-CpG in the presence of DTT. To investigate the time-dependent release profiles, the released CpGs were quantitatively assessed by OliGreen assay after incubation in the presence of DTT for predetermined times, as shown in Fig. 3B . After 5 h of incubation, 17.0 ± 2.0 and 39.7 ± 7.0 ng of CpGs were released from PPM-CpG and PPM-s-s-CpG, respectively. Considering that the total amounts of CpGs per PPM-CpG and PPM-s-s-CpG were 113.2 and 98.9 ng, respectively, 15.0 and 40.1% of CpGs were released from PPM-CpG and PPM-s-s-CpG after 5 h of incubation. Approximately 2.3-fold higher amount of CpGs was released from PPM-s-sCpG compared to that released from PPM-CpG, which indicates the facile release of CpGs from PPM-s-s-CpGs by disulfide linkage. According to a previous study, glutathione is involved in the reduction in thiol compounds in Appl Biol Chem (2017) 60(3):321-326 323 the phagolysosomes of macrophages [23] . It is likely that CpG could be released from PPM-s-s-CpGs via glutathione-mediated reduction in macrophages like RAW264.7 cells.
Cytokine release
RAW264.7 cells were treated with PPM-s-s-CpGs for 8 h to examine the released levels of cytokines by ELISA. Figure 4 exhibits the quantitative analysis of two cytokines, TNF-a and IL-6. Figure 4A shows that the amounts of TNF-a triggered by CpG, PPM-s-s-CpGs, and PPM-s-sGpCs were 548.1 ± 30.1, 3205.5 ± 112.5, and 17.6 ± 10.0 pg/mL, respectively. An 11.7-fold higher induction of TNF-a was observed in cells treated with PPM-s-s-CpGs compared with that in cells treated with free CpG. In addition, noticeable induction of TNF-a was not observed in cells treated with PPM-s-s-GpCs, which suggests that specific cytokine induction is triggered by CpG-mediated pathways. Figure 4B than those induced by free CpG and PPM-s-s-GpCs, respectively. Taken together, PPM-s-s-GpCs showed negligible cytokine induction, while PPM-s-s-CpGs exhibited strong induction of TNF-a and IL-6 in RAW264.7 cells. It should be noted that direct interaction of CpG with TLR-9 seems to be crucial for TLR-9 dimerization and following activation according to previous studies [1, 24, 25] . Thus, facile release of CpGs attached onto porous microparticles via cleavable linkage could provide not only high loading efficiency due to sufficient surface area but also favorable interaction with TLR-9 in phagosome. CpGs have elicited several cytokines including TNF-a, IL-12 and IL-6 for macrophages. Expression level of each cytokine has been known to be closely related via intracellular NF-rB pathway [26] . Although only representative two types of cytokines, TNF-a and IL-6, were assessed for macrophages in this study, evaluation study of PPM-s-s-CpGs could be examined using other types of cytokines, e.g., IL-12 and antigen-presenting cells, e.g., dendritic cells in our next study.
In this study, we successfully fabricated CpG-conjugated polydopamine-coated porous PLGA microparticles via cleavable disulfide linkages. CpGs were readily released from PPM-s-s-CpGs in reductive conditions. The released CpGs exhibited significantly enhanced induction of TNF-a and IL-6 in RAW264.7 cells. The PPM-s-sCpGs can serve as immune-stimulating adjuvants to enhance the immune response of vaccines. 
